Gilead Sciences

Gilead Sciences’ EVP sells 5,000 Shares of Company’s Stock

Gilead Sciences’ EVP sells 5,000 Shares of Company’s Stock

Gregg H. Alton, Executive Vice President of Corporate and Medical Affairs at Gilead Sciences, Inc. sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, January 8th.

News: 
Company: 

Evidence Turning in Favor of Gilead’s HCV Drug, Sovaldi

Evidence Turning in Favor of Gilead’s HCV Drug, Sovaldi

A lot of discussion is taking place in the US about Gilead's Hepatitis C (HCV) drug, Sovaldi. The major controversy surrounding the drug is its cost, which is $84,000 in the U. S. for a full course of treatment. Insurers and pharmacy benefit managers (PBMs) are quite angry over the price of the drug and find it quite costly.

On the other hand, the UK's National Institute for Health and Care Excellence (NICE) has lately given approval to the drug as being cost-effective. It has recommended the drug for sub-groups of patients.

Location: 
Company: 

Gilead Sciences Exploited Monopoly Right to Set $1,000 for One Pill of Hepatitis C Drug

Gilead Sciences Exploited Monopoly Right to Set $1,000 for One Pill of Hepatitis

Is it right for pharmaceutical companies to charge patients too high for life saving drugs that they innovate and eventually bring in the market after getting the approval? As per a report about earnings of Gilead Sciences, the company has earned $6 billion in profits within six months from the sales of the hepatitis C drug, Sovaldi.

Company: 

US Health Insurer AHIP Considers Gilead’s Solvadi Overpriced

US Health Insurer AHIP Considers Gilead’s Solvadi Overpriced

US Health insurance group America's Health Insurance Plans has condemned the high price of hepatitis C treatment developed by Gilead Sciences Inc. The treatment has recently faced criticism from lawmakers and individual payers.

The hepatitis treatment Solvadi costs nearly $84,000 for complete course. AHIP statement said that Solvadi has shown very good results but the high cost of treatment cannot be justified by the company.

Location: 
Company: 

Democrats Raise Questions on High Cost of Gilead’s Hepatitis Drug

Democrats Raise Questions on High Cost of Gilead’s Hepatitis Drug

Gilead is endeavoring to develop a promising drug by combination of Sovaldi with GS-5816, which would surely cure all types of hepatitis C with a single pill. With the recent development of interferon-free oral hepatitis c drug, Sovaldi, Gilead is in headlines for the past few days. However, the treatment cost will be quite high and this has invited criticism from many leaders.

News: 
Location: 
Company: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More